Since March 2020, the COVID-19 pandemic has led to the need to re-think the delivery of services to patients with chronic dysimmune neuropathies. Telephone/video consultations have become widespread but have compounded concerns about objective evaluation. Therapeutic decisions need, more than ever before, to be considered in the best interests of both patients, and society, while not denying function-preserving/restoring treatment. Immunoglobulin therapy and plasma exchange, for those treated outside of the home, expose patients to the hazards of hospital or outpatient infusion centers. Steroid therapy initiation and continuation pose increased infectious risk. Immunosuppressant therapy similarly becomes highly problematic, with the risks of treatment continuation enhanced by uncertainties regarding duration of the pandemic. The required processes necessitate considerable time and effort especially as resources and staff are re-deployed to face the pandemic, but are essential for protecting this group of patients and as an integral part of wider public health actions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264511 | PMC |
| http://dx.doi.org/10.1002/mus.26896 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Which workup should be performed after a pregnancy complicated with vasculo-placental disorder?].
Rev Med Interne
September 2024
Service d'anatomopathologie, CHU de Brest, hôpital Morvan, Brest cedex, France; EA4685, LIEN, Inserm, universiyé de Brest, 29200 Brest, France.
Article Synopsis
- - Vasculo-placental disorders are pregnancy complications arising from issues with the placenta's blood vessels, such as pre-eclampsia, HELLP syndrome, and stillbirth faced due to vascular problems.
- - Pre-eclampsia in severe cases warrants testing for antiphospholipid syndrome (APS) and examining the placenta afterwards can reveal various anatomical and inflammatory issues that may contribute to complications like intrauterine growth retardation (IUGR).
- - A follow-up consultation two months post-delivery helps assess the causes of these disorders and provides guidance on managing future pregnancies and addressing cardiovascular health.
Immunoglobulin use in neurology: a practical approach.
Pract Neurol
August 2024
UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK
Article Synopsis
- Human immunoglobulin (IVIg) is used to treat various immune-mediated neurological disorders, focusing on its effects in both acute inflammatory diseases and chronic disease management.
- The review examines how IVIg works and its evidence in treating conditions like Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in the UK and Australia.
- It also discusses the pros and cons of IVIg, emphasizes practical aspects like informed consent and risk management, and addresses the careful use of this costly blood product.
Immunogenicity of SARS-CoV-2 vaccines in patients treated with chronic double filtration plasmapheresis.
J Clin Apher
June 2024
Department of Nephrology-Dialysis-Apheresis, Nîmes University Hospital, Nîmes, France.
Background: The impact of chronic therapeutic plasmapheresis on humoral response following COVID-19 vaccination is poorly documented, especially among patients treated with double filtration plasmapheresis (DFPP).
Objectives: This retrospective single-center study evaluated the humoral response after SARS-CoV-2 vaccination and studied anti-SPIKE seropositivity and antibody dynamics in patients with chronic DFPP at our institution.
Method: All patients undergoing chronic DFPP at a tertiary center in France from December 2020 to November 2022 were included.
Diagnosis, management and therapeutic options for eosinophilic esophagitis.
Curr Opin Allergy Clin Immunol
June 2024
Department of Medicine and Medical Therapeutics, University of Pavia.
Article Synopsis
- Eosinophilic esophagitis (EoE) is a chronic condition that causes tissue damage in the esophagus, impacting quality of life; recent advances focus on diagnosing and managing the disease.
- New diagnostic methods classify EoE into three distinct endotypes based on inflammatory features and symptoms, which helps tailor treatment.
- Two new medications, oro-dispersible budesonide and dupilumab, target EoE specifically, and a collaborative approach between gastroenterologists and allergist-immunologists is essential for effective management of the disease.
Inflammatory sensory neuronopathies.
Rev Neurol (Paris)
December 2024
Department of Neurology, University Hospital of Saint-Etienne, 42055 Saint-Étienne cedex, France. Electronic address:
Inflammatory sensory neuronopathies are rare disorders mediated by dysimmune mechanisms targeting sensory neurons in the dorsal root ganglia. They constitute a heterogeneous group of disorders with acute, subacute, or chronic courses, and occur with cancer, systemic autoimmune diseases, notably Sjögren syndrome, and viral infections but a noticeable proportion of them remains isolated. Identifying inflammatory sensory neuronopathies is crucial because they have the potential to be stabilized or even to improve with immunomodulatory or immunosuppressant treatments provided that the treatment is applied at an early stage of the disease, before a definitive degeneration of neurons.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!